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Summary Children with sickle cell disease (SCD) are at high risk of severe infection
with Streptococcus pneumoniae (SP). From 2002, all children aged <5 years in the UK
with SCD were recommended 7-valent pneumococcal conjugate vaccine (PCV-7) in
infancy and 23-valent pneumococcal polysaccharide vaccine boosting, in addition to
regular penicillin prophylaxis. Our objective was to determine the nasopharyngeal
(NP) carriage rate of SP in children aged <5 years with SCD before and after vaccina-
tion with PCV-7 (by vaccine, cross-protection and non-vaccine serotypes). NP swabs
were obtained from 63 children attending the Royal London Hospital or Newhampneumoniae
General Hospital paediatric haematology clinic between April 2001 and April 2002.
Later, NP swabs were obtained from 43 children attending the clinic between June
and December 2004 after a PCV-7 vaccination programme. All SP isolated by culture
were serotyped and susceptibility to penicillin measured. In the ﬁrst study group,
ith 1 sample containing 2 different serotypes, giving a car-13 samples grew SP w
riage rate of 21%. Four (31%) were intermediately susceptible to penicillin. In the
second group overall NP carriage rate had decreased to 9% (n = 4), and the proportion
 Part of this study was presented at the 10th Congress of the European Hematology Association Stockholm, Sweden,
June 2—5, 2005.
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directly or indirectly covered by the PCV-7 vaccine fell from 13/14 to 2/4 (P = 0.11).
One (25%) of these isolates was intermediately susceptible to penicillin. The introduc-
tion of PCV-7 appears to be associated with a shift in distribution of serotypes carried
by children with SCD. This may have implications for vaccine effectiveness.
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were set up on ISO/blood agar according to British
Society for Antimicrobial Chemotherapy (BSAC)
guidelines. If pneumococci resistant to oxacillin© 2008 King Saud Bin Ab
Ltd. All rights reserved.
ntroduction
treptococcus pneumoniae (SP) has been shown to
e the most frequent pathogen isolated in fatal
vents associated with infection in children with
ickle cell disease (SCD) less than 5 years of age
1]. Penicillin prophylaxis for these children has
een a recommended practice in the UK since
996 [2], but this has proved inadequate, even in
ombination with 23-valent pneumococcal polysac-
haride vaccine (PPV-23) [3—5]. Non-compliance
ith antibiotic prophylaxis, emergence of penicillin
esistant pneumococci and lack of immunological
emory associated with PPV-23 vaccination are
mong proposed causes of failure [4—8]. Therefore,
evelopment of more highly immunogenic vaccines,
.g., by linking pneumococcal polysaccharides or
arts of them to protein carriers has been achieved
9—11].
The 7-valent pneumococcal conjugate vaccine
PCV-7) has been recommended in the UK since
anuary 2002 for children less than 2 years of age
onsidered to be at risk. PCV-7 covers the follow-
ng 7 serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F. This
accine has already been shown to be effective at
educing incidence of invasive pneumococcal dis-
ase (IPD) in both healthy children and, by herd
rotection, adults in the United States [12,13].
There is little data on SP carriage in UK children
t high-risk of developing IPD and on carriage rates
ost vaccine introduction, so this study was set up
o address this gap.
Therefore, the objectives of this study were to
etermine the nasopharyngeal (NP) carriage rate of
P and serotype distribution both before and after
he introduction of PCV-7 in a group of UK children
ith SCD.
ethods
hildren less than 5 years of age with homozy-
ous sickle cell disease (HbSS), haemoglobin SC
isease (HbSC), haemoglobin S beta thalassaemia
HbS) or other sickle haemoglobinopathies were
ecruited from the Paediatric Haematology clinic
f the Royal London and Newham General Hos-
itals between April 2001 and April 2002. These
w
t
w
aziz University for Health Sciences. Published by Elsevier
hildren belonged to a neonatal cohort screened
o have SCD on haemoglobin variant analysis of
ord blood samples at birth [14]. Children from the
ame cohort were recruited again between June
nd December 2004, after the introduction of a vac-
ination programme in high-risk children less than
years. We attempted to use the largest sample
ize from this birth cohort in the two combined clin-
cs. Children in both phases were asymptomatic and
n routine penicillin prophylaxis according to our
utpatient protocol (oral phenoxymethylpenicillin
25mg twice daily). The study was approved by the
thics Committee of Barts and the London Queen
ary’s School of Medicine and Dentistry, London,
K.
The inclusion criteria were:
. Children with SCD diagnosed by haemoglobin
electrophoresis.
. Aged less than 60 months at the time of recruit-
ment.
. On regular follow up at the Sickle Cell Clinics of
the Royal London or Newham General Hospitals.
The Exclusion criteria were:
. Children aged more than 60 months at the time
of recruitment.
. Not residents of East London or not on regular
follow up at the Sickle Cell Clinics of the Royal
London or Newham General Hospitals.
. Hospitalised patients or those on antibiotics
other than routine penicillin prophylaxis.
Informed consent was obtained from the par-
nts after explaining the study in detail. An NP
wab was obtained from each child with dry, cot-
on tipped aluminium wire swabs. The swabs were
ransported to the microbiology laboratory at St.
homas’s Hospital, London, and set up for culture
ithin 4 h. They were incubated at 36 ◦C in CO2
nd examined at 24 h for draughtsmen colonies,
ensitive to 5g Optochin discs. Sensitivity platesere identiﬁed, an E-test was carried out to deﬁne
he penicillin MIC. Those with an MIC <1g/ml
ere described as penicillin susceptible, those with
n MIC 2g/ml were considered intermediately
w
d
n
o
h
d
c
r
r
t
p
b
p
D
N
h
b
I
r
l
p
d
w
s
p
P
o
P
2
c
b
s
s
a
P42
susceptible to penicillin and those with an MIC of
>4g /ml were described as resistant [15]. Isolated
pneumococci were sent to the reference laboratory
for serotype identiﬁcation.
Fisher’s exact test was used for comparing
categorical variables and two-sample t-test for con-
tinuous variables.
Results
First phase
NP swabs were collected from 63 patients with SCD
between April 2001 and April 2002, prior to the
introduction of PCV-7. The demographic character-
istics and diagnoses are shown in Table 1. Thirteen
samples grew SP with 1 sample containing 2 differ-
ent serotypes, giving an overall carriage rate during
the pre-vaccination study period of 21%. Ten carried
isolates were fully covered by PCV-7 (6B× 2, 9V× 1,
14× 4, 19F× 2, 23F× 1), 3 others were potentially
covered by the vaccine due to cross-protection (6A
×2, 19A ×1) and 1 isolate (35F) was not covered
by the vaccine: thus 13 of 14 isolates were directly
or indirectly covered by PCV-7. Four isolates (22%)
were intermediately susceptible to penicillin. They
were serotypes 14 (n = 2) and 6B (n = 2). None were
fully resistant to penicillin. Penicillin prophylaxis
uptake was 100% according to parental history.
Second phase
NP swabs were collected from 43 patients after
the introduction of PCV-7 at 2, 3 and 4 months
of age. The demographic characteristics and diag-
noses are shown in Table 1; patients in the second
cohort were older than those in the ﬁrst cohort
(37 months vs. 25 moths, P < 0.01), and there were
greater proportion of female subjects in the second
cohort compared to the ﬁrst (60% vs. 35%, P = 0.01).
Four samples grew SP giving a carriage rate of
9%. Three could be serotyped and one of them
was fully covered by PCV-7 (23F), a further one
b
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Table 1 Demographic characteristics of the patients in bo
Characteristics First phase
Sample size 63
Mean age (range) 25 (1—56) months
Male:Female 41:22
Diagnosis
HbSS 86% (n = 54)
HbSC 13% (n = 8)
Others 1% (n = 1)E. Alexander et al.
as potentially covered by the vaccine (19A× 1)
ue to cross-protection, another one was not was
ot covered by the vaccine (15B), and the last
ne was non-typeable. One isolate, serotype 23F,
ad a penicillin MIC >1.5g/ml and was therefore
escribed as intermediately susceptible to peni-
illin. All of the children had received penicillin
egularly, according to parental history. The car-
iage rate of pneumococcus decreased from 21% in
he ﬁrst phase to 9% in this phase (P = 0.18). The
roportion of isolates directly or indirectly covered
y the PCV-7 vaccine fell from 13/14 in the ﬁrst
hase to 2/4 in the second phase (P = 0.11).
iscussion
asopharyngeal pneumococcal carriage rates in
ealthy young children in developed countries can
e as high as 54%, compared to 4% in adults [16—18].
n children with sickle cell disease, the NP carriage
ate is lower, possibly due to antibiotic prophy-
axis [19]. Data from our study yielded an initial
neumococcal carriage rate of 21% before the intro-
uction of PCV-7 in children younger than 2 years
ith sickle cell disease. This is higher than in other
tudies involving children with sickle cell disease
erformed in the USA prior to the introduction of
CV-7 [19], but lower than an overall carriage rate
f 34.2% found in healthy children in the UK [20].
rior studies have shown that vaccination with PPV-
3 has no signiﬁcant effect on carriage [4]; hence
arriage rates are lower in children with SCD, not
ecause of vaccine but because of other factors
uch as antibiotic prophylaxis and other broader-
pectrum antibiotics given when these children are
dmitted to hospital.
Recent studies in the USA and Greece have shown
CV-7 to be not only effective at preventing IPD
ut also in reducing NP carriage [21—23]. Studies
n Israel and Greece have shown reduction in the
arriage of vaccine types and of antibiotic-resistant
neumococci in the nasopharynx, subsequent to
he introduction of PCV-7 [18,21]. Almost all the
th phases
Second phase P value
43
37 (13—59) months <0.01
17:26 0.01
84% (n = 36) 0.79
12% (n = 5) 1.0
4% (n = 2) 0.56
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Rneumococcal carriage in children with sickle cell d
erotypes isolated in the initial phase of the study
ould have been covered by PCV-7 (with the excep-
ion of one isolate of 35F) as there may be
ross-protection between antibodies to 6A and 6B,
nd 19A and 19F. One of the positive cases isolated
n the second phase of the study was non-typeable,
ut the remaining 3 were; these were 15B, 19A,
nd 23F. Serotype 23F is covered by both PCV-7 and
PV-23, while serotype 19A is covered by PPV-23
nd also indirectly covered by PCV-7 due to cross-
rotection, but serotype 15B is only covered by
PV-23 and not by PCV-7 at all. Thus serotype 23F
as the only vaccine serotype isolated (and covered
y both polysaccharide and conjugate vaccines).
In the second phase one child had the non-
accine serotype 15B, and another child had
on-typeable strain. Thus, between the two phases
f the study there appears to have been a relative
ecrease in vaccine serotype carriage, albeit chil-
ren in the second phase being older and less likely
o carry pneumococci. Interestingly, the proportion
f isolates directly or indirectly covered by PCV-7
accine decreased from a large majority of 13/14
n the ﬁrst phase to just 2/4 in the second phase, a
ifference that did not however reach signiﬁcance
P = 0.11).
The concern is that current vaccines will not
nduce a protective immune response against non-
ypeable strains, even though they are associated
ith IPD. The main virulence factor of the pneumo-
occus is the polysaccharide capsule and previous
tudies have shown that capsular serotypes inde-
endently inﬂuence the outcome from IPD, such
hat the virulence of pneumococcal serotypes have
een considered in the design of the conjugate vac-
ines [8,24,25]. Our study shows an emergence in
he carriage of both non-vaccine and non-typeable
erotypes that were not covered by any available
onjugate vaccine.
In this study 4 initial isolates were interme-
iately susceptible to penicillin, they were of
erotypes 14 and 6B (2 each), which are both
resent in PCV-7. The only isolate from the second
hase of the study with intermediate penicillin sus-
eptibility was the non-typeable strain. Again, our
tudy shows that although NP carriage of pneumo-
occus appears to be reduced, resistant strains are
merging which are not covered by the vaccine.
In this study, nasopharyngeal carriage rate of SP
n children with SCD decreased signiﬁcantly after
he introduction of PCV-7. Initial carriage rates
ere lower than in healthy children, probably due
o the antibiotics these children receive, both as
rophylaxis and as treatment. Interestingly, there
as an emergence of non-typeable and non-vaccine
erotype isolates among those in whom NP swabsse 43
ere positive. This may indicate that modern pneu-
ococcal prophylaxis is encouraging the emergence
f non-vaccine serotypes and less common non-
ypeable strains. Pneumococcus is known to be able
o ‘‘switch’’ capsules by recombination of capsular
enes between clones [11,24,26]. This is likely to
e the mechanism by which serotypes are becoming
on-typeable.
Due to small sample size it is difﬁcult to gener-
lise the results of this study to the beneﬁt of PCV-7
n general population, but it is important to ensure
hat children with sickle cell disease are offered the
est protection available including routine peni-
illin prophylaxis as well as pneumococcal vaccines.
mmunisation with a pneumococcal conjugate vac-
ine that covers a higher number of serotypes (e.g.,
CV-9 or PCV-11) may provide better protection
han the currently available vaccine [27].
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